Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LV20.19 CAR-T cells |
Synonyms | |
Therapy Description |
LV20.19 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) comprising single chain variable fragments targeting CD19 and CD20 coupled to CD3zeta and TNFRSF9 (CD137; 4-1BB) signaling domains, which potentially induce antitumor activity (PMID: 33020647, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LV20.19 CAR-T cells | Autologous CAR-20/19-T cells|4-1BB-CD3zeta LV20.19 CAR T cells | CD19 Immune Cell Therapy 65 CD20 Immune Cell Therapy 13 | LV20.19 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) comprising single chain variable fragments targeting CD19 and CD20 coupled to CD3zeta and TNFRSF9 (CD137; 4-1BB) signaling domains, which potentially induce antitumor activity (PMID: 33020647, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|